BioAge’s NLRP3 inhibitor has shown potential to reduce high-sensitivity C-reactive protein (hsCRP), a key marker of ...

MRM Health has received clearance from the FDA for its IND application, enabling the company to start the STARFISH-UC Phase ...

GSK will be filing for approval of bepirovirsen in hepatitis B to global regulatory authorities based on the Phase III data.

The Mount Sinai TCC has introduced an AI clinical trial matching platform, PRISM, to improve access to cancer research ...

In the Phase Ib JADE trial, OLN324 demonstrated both faster and greater retinal drying versus Vabysmo in patients with DME, ...

NRG Therapeutics has dosed the first participants in its Phase I clinical trial of NRG5051, being developed as a ...

In the ongoing study (NCT06700538), Arrowhead’s candidate, called ARO-INHBE, plus Zepbound, doubled weight loss and tripled ...

Neumora Therapeutics’ oral Alzheimer’s disease agitation drug has shown benefit, reducing agitation, in a Phase Ib trial.

Medical Devices includes a session from a regulatory expert on how companies can align their research between regions.

While obexelimab failed to best Uplizna in terms of efficacy, Zenas will still file for the drug’s approval in IgG4-RD.

MetaVia will now be investigating the candidate at two different titration levels in 16-week trials for obesity.

The trial enrolled 44 participants with symptomatic oHCM. Credit: NMK-Studio / Shutterstock.com. Bristol Myers Squibb (BMS) has announced positive top line results from the Phase III SCOUT-HCM trial ...